Adoptive Transfer of Cloned Melanoma-Reactive T Lymphocytes for the Treatment of Patients with Metastatic Melanoma

Journal of Immunotherapy

Volumn 24, Issue 4, 2001, Pages 363-373

  Dudley, Mark E ^a   Wunderlich, John ^a   Nishimura, Michael I ^a   Yu, David ^a   Yang, James C ^a   Topalian, Suzanne L ^a   Schwartzentruber, Douglas J ^b   Hwu, Patrick ^b   Marincola, Francesco M ^b   Sherry, Richard ^b   Leitman, Susan F ^b   Rosenberg, Steven A ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Gp100; Immunotherapy; Interleukin 2; Melanoma; T cell clone

Indexed keywords

GAMMA INTERFERON; GLYCOPROTEIN GP 100; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; MELANOMA ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ADOPTIVE TRANSFER; ADULT; AGED; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; ASSAY; BLOOD SAMPLING; CANCER STAGING; CELL TRANSFER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; FEMALE; HOST; HUMAN; IMMUNIZATION; IMMUNOTHERAPY; LYMPHOCYTIC INFILTRATION; MALE; MELANOMA; METASTASIS; MOLECULAR CLONING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE;

ADULT; AGED; CLONE CELLS; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; INTERLEUKIN-2; MALE; MELANOMA; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PEPTIDE FRAGMENTS; T-LYMPHOCYTES;

EID: 17944379652     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-200107000-00012     Document Type: Article

References (22)

1. Dudley ME. Cell transfer therapy: basic principles and preclinical studies. In: Rosenberg SA, ed. Principles and Practice of the Biologic Therapy of Cancer, 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2000, pp 305-21.
2. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17: 2105-16.
3. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4: 321-7.
4. Dudley ME, Nishimura MI, Holt AKC, Rosenberg SA. Anti-tumor immunization with a minimal peptide epitope (G9-209-2M) leads to a functionally heterogeneous CTL response. Cancer J 2000; 6: 69-77.
5. Aruga A, Shu S, Chang AE. Tumor-specific granulocyte/macrophage colony-stimulating factor and interferon gamma secretion is associated with in vivo therapeutic efficacy of activated tumor-draining lymph node cells. Cancer Immunol Immunother 1995; 41: 317-24.
6. Barth Jr, RJ, Mule JJ, Spiess PJ, Rosenberg SA. Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. J Exp Med 1991; 173: 647-58.
7. Zeh HJ, Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 1999; 162: 989-94.
8. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333: 1038-44.
9. Tan R, Xu X, Ogg GS, et al. Rapid death of adoptively transferred T cells in acquired immunodeficiency syndrome. Blood 1999; 93: 1506-10.
10. Brodie SJ, Lewinsohn DA, Patterson BK, et al. In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nat Med 1999; 5: 34-41.
11. Yee C, Gilbert MJ, Riddell SR, et al. Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus. J Immunol 1996; 157: 4079-86.
12. Rosenberg SA, Yannelli JR, Yang JC, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994; 86: 1159-66.
13. Nishimura MI, Kawakami Y, Charmley P, et al. T-cell receptor repertoire in tumor-infiltrating lymphocytes. Analysis of melanoma-specific long-term lines. J Immunother 1994; 16: 85-94.
14. McKee MD, Schemitsch EH, Stephen DJ, et al. Functional outcome following clavicle fractures in polytrauma patients [abstract]. J Trauma. 1999: 47;616.
15. Pockaj BA, Sherry RM, Wei JP, et al. Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Cancer 1994; 73: 1731-7.
16. Dudley ME, Ngo LT, Westwood J, Wunderlich JR, Rosenberg SA. T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes. Sci Am 2000; 6: 69-77.
17. Lee DS, White DE, Hurst R, Rosenberg SA, Yang JC. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy. Cancer J Sci Am 1998; 4: 86-93.
18. Rosenberg SA, Aebersold P, Cornetta K, et al. Gene transfer into humans—immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 1990; 323: 570-8.
19. Mehal WZ, Juedes AE, Crispe IN. Selective retention of activated CD8+ T cells by the normal liver. J Immunol 1999; 163: 3202-10.
20. McKinney DM, Lewinsohn DA, Riddell SR, Greenberg PD, Mosier DE. The antiviral activity of HIV-specific CD8+ CTL clones is limited by elimination due to encounter with HIV-infected targets. J Immunol 1999; 163: 861-7.
21. Mitsuyasu RT, Anton PA, Deeks SG, et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood 2000; 96: 785-93.
22. Walker RE, Bechtel CM, Natarajan V, et al. Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood 2000; 96: 467-74.